TRCT
DNA icon

Tower Research Capital (TRC)’s Ginkgo Bioworks DNA Stock Holding History

Tower Research Capital (TRC)’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$56.8K Buy
9,269
+8,253
+812% +$68.6K ﹤0.01% 2632
2025
Q4 		$8.44K Sell
1,016
-129
-11% -$1.39K ﹤0.01% 3948
2025
Q3 		$16.7K Sell
1,145
-1,636
-59% -$19.6K ﹤0.01% 3462
2025
Q2 		$31.3K Sell
2,781
-14,752
-84% -$114K ﹤0.01% 3367
2025
Q1 		$99.9K Buy
17,533
+561
+3% +$5.71K ﹤0.01% 1770
2024
Q4 		$167K Sell
16,972
-3,899
-19% -$33.4K ﹤0.01% 1837
2024
Q3 		$170K Buy
20,871
+17,243
+475% +$173K ﹤0.01% 1768
2024
Q2 		$48.5K Buy
3,628
+560
+18% +$16.7K ﹤0.01% 3123
2024
Q1 		$142K Sell
3,068
-7,654
-71% -$396K ﹤0.01% 1632
2023
Q4 		$725K Buy
10,722
+10,156
+1,794% +$622K 0.01% 1080
2023
Q3 		$40.9K Sell
566
-142
-20% -$11.4K ﹤0.01% 2716
2023
Q2 		$52.7K Sell
708
-3,206
-82% -$190K ﹤0.01% 2539
2023
Q1 		$208K Sell
3,914
-964
-20% -$61.1K 0.01% 1344
2022
Q4 		$330K Sell
4,878
-465
-9% -$42.8K 0.01% 959
2022
Q3 		$667K Buy
5,343
+3,084
+137% +$368K 0.01% 918
2022
Q2 		$215K Buy
2,259
+2,213
+4,811% +$270K ﹤0.01% 1716
2022
Q1 		$7K Buy
46
+15
+48% +$2.92K ﹤0.01% 4709
2021
Q4 		$10K Buy
31
+13
+72% +$6.17K ﹤0.01% 4550
2021
Q3 		$8K Buy
+18
New +$8.76K ﹤0.01% 4528

Other funds holding DNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.18B AUM 27.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tower Research Capital (TRC)'s DNA Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Ginkgo Bioworks (DNA) stake by 812% in Q1 2026, buying an estimated $68.6K and bringing the position to 9,269 shares worth $56.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2632.

Tower Research Capital (TRC) first reported a position in DNA in Q3 2021 and has held it in 19 quarters since. The position peaked at $725K in Q4 2023. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

  • Tower Research Capital (TRC) held 9,269 shares of Ginkgo Bioworks worth $56.8K as of Q1 2026.
  • Tower Research Capital (TRC) bought 8,253 Ginkgo Bioworks shares in Q1 2026, an estimated $68.6K.
  • Ginkgo Bioworks made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2632 holding.
  • Tower Research Capital (TRC) first reported a position in Ginkgo Bioworks in Q3 2021 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s Ginkgo Bioworks position peaked at $725K in Q4 2023.
  • 174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.